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Background: Although the Human Papillomavirus (HPV) vaccine is registered in Australia for females aged 9 to
45 years, females aged 27 to 45 years have shown limited vaccine uptake. Our study explored general practitioners’
(GPs) views concerning HPV vaccination of females in this age group, with particular focus on the barriers and the
facilitators to the delivery of the HPV vaccine.
Methods: Semi-structured telephone interviews were conducted with 24 randomly selected general practitioners
from metropolitan Melbourne. Questions were based on a theoretical framework that explained the barriers and
facilitators to professional behaviour change.
Results: According to the GPs, the major barriers to the uptake of the HPV vaccine included the cost of the vaccine,
time constraints, and the three-dose schedule. Other barriers that were identified included GPs’ and patients’ beliefs that
females in this age group were at low risk of contracting HPV, lack of awareness about the vaccine, and uncertainty
about the benefits of this vaccine for females in this age group. In contrast, the facilitators that were identified included
the availability of the vaccine on site, the availability of vaccine clinics or nurses for administering the vaccine, the
availability of information related to the vaccine either on site or online, and positive opinions from experts in the field.
Conclusions: Our study has identified some of the barriers and facilitators to the delivery and uptake of the HPV
vaccine in females aged 27 to 45 years, as perceived by GPs. Further studies should be conducted to determine which
of these should be targeted or prioritised for intervention. The views of women in this age group should also be
considered as these would also be influential in designing effective intervention strategies for improving the delivery
and uptake of the HPV vaccine.
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Infection with the human papillomavirus (HPV) is the
most significant risk factor for cervical cancer, the second
most common cancer in women [1]. There are currently
two vaccines against HPV that are available in Australia:
GardasilW (Merck & Co., Whitehouse Station, NJ USA)
and CervarixW (GlaxoSmithKline Biologicals, Rixensart,
Belgium). Both vaccines demonstrate a high level of effi-
cacy against HPV types 16 and 18 [2], which are classified
as “high oncogenic risk” [3]. In Australia, GardasilW is reg-
istered for use in females aged 9 to 45 years and in males
aged 9 to 26 years [4], while CervarixW is registered for
use in females aged 10 to 45 years, but not in males [4].* Correspondence: danielle.mazza@monash.edu
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unless otherwise stated.In April 2007, a government-funded universal HPV
vaccination program was introduced in Australia [5], the
first country to do so. Initially under this program, females
aged 12 to 26 years received the vaccine free of charge.
School-based immunisation programs targeted girls
aged 12 to13 years, and free vaccines were provided to
general practice clinics to immunise females aged up to
27 years. Free school-based vaccination for girls aged
12 to 13 years still continues to this day; however, from
December 2009, females aged 13 years and over in-
curred a private cost of approximately AUD$150 for
each of the three vaccines required to complete the
course (a total cost of AUD$450) [5]. In 2012, a similar
HPV vaccination program for boys aged 9–18 years of age
was also introduced in Australia [6,7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HPV vaccine uptake in Australia, particularly through the
school-based immunisation programs where a one-dose
coverage of greater than 80% and a three-dose coverage of
approximately 70% has been achieved [5,8]. However, the
uptake in females aged up to 26 years who had access to
the vaccine free of charge up until December 2009, but
were not part of the school-based immunisation pro-
grams, may not be as high. One Australian study reported
that only 58% of females aged 26 years and under had re-
ceived at least one injection, with even fewer (26.9%) hav-
ing completed the course [9].
Up to two-thirds of females aged 24 to 45 years are esti-
mated to potentially be susceptible to all four HPV types
present in GardasilW (6, 11, 16, and 18) [10], yet very little
is known about HPV vaccine uptake in this population
[9,11]. A second peak of HPV prevalence has also been
demonstrated in the fourth and fifth decades of life [12],
which could be prevented by HPV vaccination. Although
information on the efficacy of HPV vaccines in this age
group is limited, one study has reported that GardasilW is
highly effective in preventing HPV-related diseases in fe-
males aged 15 to 45 years who were HPV naïve [13]. Such
data is not yet available for CervarixW; however, immuno-
genicity and safety data from a clinical trial indicate that
this vaccine can induce a robust and persistent immune
response in females aged 26–55 years [14].
In Australia, HPV vaccination of females aged 27 to
45 years primarily occurs in general practice, but little is
known about the barriers to and facilitators of the delivery
of the HPV vaccine in this population because previous
studies have mainly focused on those aged 26 years and
under [15-17]. Also, most studies that examined the be-
liefs of general practitioners (GPs) toward HPV vaccin-
ation were conducted outside of Australia [18-20], which
limits the generalisability of the results to an Australian
population. Consequently, the aim of our study was to in-
vestigate the barriers and facilitators to HPV vaccination
in females aged 27 to 45 years in Australia, as perceived
by GPs.
Methods
This study was approved by the Monash University
Human Research Ethics Committee and informed con-
sent was obtained from all participants whose details
were deidentified to maintain confidentiality.
To obtain a range of views that reflected diverse general
practices, purposive sampling was used to recruit GPs. Let-
ters of invitation were sent to a random sample of 400 GPs
located in metropolitan Melbourne, Australia who were
listed in the Australasian Medical Publishing Company
database of Australian medical practitioners. An incentive
of AUD$200 was offered for participation in the study.
After two weeks, reminder letters were sent to GPs whohad not yet responded. Of the 400 GPs selected, 44 showed
interest in participating; however, only 24 GPs could be
contacted within a reasonable timeframe for an interview.
Semi-structured telephone interviews were conducted
by KP between November and December 2010, and the
interview questions were based on the theoretical do-
mains framework (TDF) [21] (Table 1). The TDF has
been used in a number of qualitative studies to investi-
gate the barriers and facilitators to the implementation
of evidence-based practice in various health care settings
[22-25]. Telephone interviews were conducted because
of the difficulty in visiting some of the GPs due to their
varying locations. The interviews were recorded using a
digital voice recording device and then transcribed, with
each transcript reviewed by the interviewer to ensure
accuracy. The verified transcripts were imported into
NVivo qualitative data analysis software (Version 7, QSR
International Pty Ltd, Burlington, MA, USA) and a de-
ductive process of thematic analysis was used to classify
responses within themes, which were subsequently coded
according to the domains of the TDF (Table 1) [21]. Tran-
scripts were coded by two independent reviewers, and
any disputes in coding were resolved through discussion
and resolution.
Results
The GPs (n = 24) in this study comprised of 12 males and
12 females, with a mean age of 49 years (age range = 34–
75 years). Data saturation was achieved after 15 interviews.
The three principal domains described by GPs as being
barriers and/or facilitators to HPV vaccination in fe-
males aged 27 to 45 years were: (1) environmental con-
text and resources, (2) social influences, and (3) beliefs
about consequences.
Environmental context and resources
This domain identified barriers such as vaccine cost, time
constraints, the GP’s physical work environment, the
three-dose schedule, and the lack of availability of the vac-
cine on site.
Cost
For the majority of GPs, a major barrier to HPV vaccin-
ation uptake was the cost of the vaccines to the patient,
although most GPs said that this would not prevent
them from discussing the vaccine.
“The most important problem is first of all, ‘how much
is it?’ I tell them and their jaw drops”. (GP#15, female,
age unknown)
Several GPs also indicated that patients were not will-
ing to spend AUD$450 as they did not view HPV vaccin-
ation as a high priority.
Table 1 Interview questions and their corresponding construct domains
Construct domain Question
Knowledge What do you know about the HPV vaccine?
Do you think there are any gaps in your knowledge of the vaccine?
What do you know about HPV vaccination guidelines for women aged 27 to 45?
How efficacious do you think the vaccine is in this age range?
How strong do you think the evidence for vaccinating women in this age range is?
Skills How easy or difficult do you find performing HPV vaccination in your context?
How competent are you in administering the vaccine?
Social/professional role and identity Do you feel a professional responsibility to encourage HPV vaccination? Why/why not?
From an ethical standpoint, do you feel an ethical obligation to encourage HPV vaccination?
Why/why not?
Are there any other professional standards or guidelines that might conflict with
recommending the HPV vaccine?
Beliefs about capabilities How confident are you counselling women about the HPV vaccine?
How confident are you in dealing with the issues inherent in HPV vaccination?
Beliefs about consequences How beneficial do you think it would be for women in the 27 to 45 year age range
to receive the vaccine?
Do you believe the benefits of HPV vaccination outweigh the costs or not?
Are there any side effects of HPV vaccination that you are concerned about?
Motivation and goals Are there any particular incentives for you to recommend or administer the HPV vaccine?
If so, what are they?
How important do you believe HPV vaccination is?
Is HPV vaccination a priority in your practice? Why/why not?
Memory, attention and decision processes What sorts of things prompt or remind you to bring up the HPV vaccine with patients?
Do you routinely recommend the HPV vaccine to women in the 27 to 45 year age range?
Have there been times when you should have discussed HPV with a patient but didn’t?
Environmental context and resources Are there other tasks or stressors which may dissuade you from taking the time to discuss
HPV with patients? If so, what are they?
Is there anything in your work environment that has in the past made it hard for you
to administer the vaccine? If so, what?
Does your practice contain all the necessary resources for providing information to
women about the HPV vaccine?
Does your practice contain all the necessary resources for administering the vaccine?
Social influences Have you ever encountered any strong opinions on the HPV vaccine?
Has there been any point at which you felt pressure from other people to encourage,
or not encourage, HPV vaccination?
Emotion Do you consider yourself to be emotionally motivated to administer the HPV vaccine to
women in the 27 to 45 year age range?
Are there any feelings, positive or negative, that might arise when you are counselling
women about the HPV vaccine?
Behavioural regulation What would need to be done in order to increase HPV administration at your practice?
How willing would you be to make these changes?
How long would these changes take?
How could these changes be maintained over the long term?
Nature of the behaviour How regularly do you initiate discussion about the HPV vaccine with women aged 27 to 45?
What kinds of questions would you ask patients before deciding to recommend the HPV vaccine?
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but their health care. So, now that is a real barrier to
people having the vaccine”. (GP#7, male, 75 years old)
Time constraints
The majority of GPs believed there was not enough time
to address HPV vaccination during a consultation, and it
was often sidelined because of other competing priorities.
“There's so many other things competing for our
attention. You know, we’re asked to promote diabetes
management and we’re asked to promote smoking
cessation and things like that so there's so many other
things that we’re trying to fit in”. (GP#17, male,
37 years old)
GPs indicated that they would be more inclined to dis-
cuss HPV vaccination if they were not so “time poor”.
They were also more likely to raise it during consulta-
tions where Pap smears, sexual health or women’s
health, contraception, sexually transmitted infections, or
other vaccines were discussed.
“If you’re looking at heart problems, you talk about
exercise. If you’re looking at sexual health, you talk about
paps and HPV vaccinations”. (GP#4, male, 58 years old)
GPs’ physical work environments
GPs’ physical work environments were either a barrier or
an enabler to HPV vaccination depending on whether the
vaccine was available on site, whether there were estab-
lished routines such as vaccine clinics, and whether nurs-
ing assistance was available for vaccine administration.
“We’ve got the vaccines on site and we sell the vaccines
and so there is ease of accessing the vaccine and
delivering it”. (GP#16, female, 39 years old)
GPs also believed that the availability of sufficient in-
formation regarding HPV vaccination for patients and
easier access to relevant information online would fa-
cilitate the delivery of the HPV vaccine to women aged
27 to 45 years.
Inconvenience
Another major barrier to HPV vaccination was the
three-dose schedule. GPs stated that patients were often
reluctant to return for further consultations to complete
the vaccination schedule. Similarly, requiring patients to
go to the pharmacy to purchase the vaccine and then re-
turn at a separate time to get vaccinated was also viewed
as a barrier by GPs who did not have the vaccine avail-
able on site. GPs felt that these inconveniences contrib-
uted to the low vaccine uptake.Social influences
This domain captured the role of patient perceptions
and the influence of other peers and professionals on
the delivery and uptake of the HPV vaccine.
Patients’ perception of risk
According to GPs, a barrier to the uptake of the HPV
vaccine in females aged 27 to 45 years was the patients’
perception of being at low risk of contracting sexually
transmitted infections.
“They felt that they actually, they didn’t need to have
it, because they were in a stable heterosexual
relationship that they’d been in for 20 years, and they
felt that their risk of getting anything was extremely
low”. (GP#20, female, 49 years old)
Some GPs stated that they experienced negative reac-
tions when raising the issue of sexually transmitted in-
fections with patients in long-term relationships, with
some patients becoming upset or insulted at sugges-
tions that their relationship was not monogamous
or stable.
Patients’ awareness
GPs indicated that they were highly influenced by their
patient’s agenda; any discussions regarding HPV vaccin-
ation depended on whether or not patients brought up
the topic. However, GPs also felt that HPV vaccination
was no longer on their patients’ agendas because it was
no longer actively promoted in the wider community.
“When it first came out, as I said, we talked a lot
more about it because people had read about it in
the press and it was quite topical”. (GP#22, female,
44 years old)
Opinion leaders
Positive opinions and information supporting HPV vac-
cination were perceived as a facilitator to the delivery of
the HPV vaccine, especially if those opinions came from
experts in the field.
“Usually when…makes a recommendation, I think, she
is quite well respected in her field and I think you'd be
foolish not to listen. Certainly I was encouraged to
hear that someone of her calibre or standing in our
profession felt it was a very good idea and we should
be encouraging people to have it, so that definitely
swayed my view”. (GP#22, female, 44 years old)
Beliefs about consequences
This domain captured GPs’ beliefs on the benefits of
HPV vaccination in females aged 27 to 45 years.
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Another barrier to the delivery of the HPV vaccine to
females aged 27 to 45 years was GPs’ belief that these
women were at a lower risk of contracting HPV because
they were more likely to be in stable, lifelong, monog-
amous relationships. GPs indicated that they were much
more likely to discuss HPV vaccination with women who
were not in a stable relationship, had just started a new
relationship, gave an indication of multiple or changing
partners, or mentioned that they had recently separated
or divorced.
“I’d discuss it in categories of women who I thought were
at risk, let’s put it that way. But people in the stable one
to one relationship I doubt if I would bother discussing it
to be quite honest”. (GP#7, male, 75 years old)
Several GPs believed that regular Pap smears for women
in this age group were more important than receiving the
vaccine, while other GPs did not feel the need to suggest
vaccinating and would merely provide the patient with in-
formation and respect their decision.
Uncertainty about consequences
A barrier to the delivery of the HPV vaccine by GPs was
their uncertainty about the benefits of this vaccine in
females aged 27 to 45 years. Many GPs voiced concerns
that the vaccine had not been adequately tested in this
age group and, therefore, the benefits of vaccinating
them were unclear.
“The efficacy of the vaccine seems to wane, so even if
you vaccinate an older woman, they’re not getting
quite as good an immune response”. (GP#1, female,
46 years old)
Several GPs stated that there were no clear guidelines
about recommending this vaccine to females in this age
group and the circumstances under which it would be
most appropriate.
“I’m not sure that there are very clear guidelines about
that”. (GP#14, female, 41 years old)
“I don’t believe that there’s anyone who says that they
know what you should do with that group”.
(GP#19, male, 50 years old)
Consequently, many GPs were reluctant to recom-
mend or administer the HPV vaccine to females in this
age group.
Many GPs also believed that the risk amongst this popu-
lation of contracting HPV varied and, therefore, vaccin-
ation should be determined individually and weighedagainst the financial cost to the patient. However, other
GPs were confident that many females aged 27 to 45 years
would derive significant benefit from HPV vaccination,
with some believing that the evidence for vaccinating
women of this age was very strong.
“I don't think there's any question about the efficacy of
the vaccine in my mind, I think the vaccine is good, I
think the trials have substantiated its efficacy so I'm
happy to give it”. (GP#10, male, 59 years old)
Side effects were not a major concern for GPs with all
stating that they believed the vaccine was safe and that
they had not seen any major adverse reactions as a result
of HPV vaccination.
Discussion
Our study explored GPs’ perception of HPV vaccination
in females aged 27 to 45 years. Using the TDF, we identi-
fied the barriers and facilitators to the delivery and up-
take of this vaccine. The major barriers included the
cost of the vaccine, time constraints, and the three-dose
schedule. Other barriers that we also identified included
GPs’ and patients’ beliefs that women in this age group
were at low risk of contracting HPV, lack of awareness
about the vaccine, and uncertainty about the benefits of
this vaccine for this age group. In contrast, the facilitators
that were identified included the availability of the vaccine
on site, the availability of vaccine clinics or nurses for ad-
ministering the vaccine, the availability of information re-
lated to the vaccine either on site or online, and positive
opinions from experts in the field who support the use of
the vaccine.
A major barrier to the delivery and uptake of HPV vac-
cination was the cost of the vaccine, which was also
reported in a previous study that evaluated the early im-
plementation of the national HPV vaccination program
for young adult women in Australia [16]. This issue is not
unique to Australia as a previous study from the US also
reported the cost of the HPV vaccine as being a barrier
to its uptake in young adult women [26]. Cost modelling
studies have also shown that the cost benefit of HPV vac-
cination becomes less favourable with increasing age [13].
In the absence of a subsidy from the Australian govern-
ment, it seems likely that recommending HPV vaccination
to women in this age group will be determined by GPs on
a case-by-case basis.
Another major barrier to the delivery of the HPV vac-
cine was the time constraints faced by GPs, which was
also reported in previous HPV vaccination studies [16,27].
GPs noted that consultations of approximately 15 minutes
were only adequate for addressing the patient’s immediate
health issues, which deprives them of the opportunity to
discuss HPV vaccination. Our results, however, may only
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given that there is no registered patient population. In
this context, preventive care is often done opportunis-
tically at the end of a patient-driven consultation. Con-
sequently, one of the key priority areas of Australia’s
National Primary Health Care Strategy [28] is the devel-
opment of systematic approaches for the delivery of
preventive care activities.
GPs also stated that the three-dose schedule was a
major barrier to the delivery and uptake of the HPV vac-
cine. Completing the HPV vaccine schedule was previ-
ously reported as an issue in another study because
following up patients and asking them to return to the
clinic to receive the second and/or third dose was often
difficult [16]. A previous study also reported that women
who had not completed the vaccine schedule were un-
likely to do so because they simply forgot or had no time
to return to the clinic [9]. One way to partially address
the difficulty of following up patients is for general prac-
tices to incorporate a recall system into practice software
or employ practice nurses to contact patients. Many of
the GPs in our study believed that the availability of vac-
cine clinics or nurses at their practices could facilitate
the delivery and uptake of the HPV vaccine.
Another barrier that we identified was the uncertainty
amongst GPs about the benefits of vaccinating women
in this age group. These uncertainties stemmed from
GPs’ beliefs that women of this age group were at low
risk of contracting HPV and the perceived lack of effi-
cacy research and clear guidelines for this patient group.
GPs indicated these women also believed that they were
at low risk of HPV infection, which contributed to the
low vaccine uptake. Patient perceptions of low risk have
been observed in previous studies with younger popula-
tions [29,30], and may be even more pronounced in
women who are in long-term, monogamous relation-
ships [31]. GPs’ beliefs regarding the lack of efficacy
data for this age group is not surprising given the pau-
city of publications regarding this at the time these
interviews were conducted. However, since 2010, one
study has reported that GardasilW is highly effective in
preventing HPV-related diseases in females aged 15 to
45 years who were HPV-naïve [13], but less effective in
those who may have had a previous HPV infection [32].
These favourable results may convince GPs of the bene-
fits of promoting HPV vaccination in older women even
though Australian guidelines do not recommend HPV
vaccination in all females aged 19 years and over be-
cause of the likelihood of exposure to at least one HPV
type, which would reduce the efficacy of the vaccine [4].
Consequently, GPs will need to consider the benefits of
HPV vaccination in older women by taking into account
previous exposure and the risk of future exposure to
HPV [4].Potential facilitators to the uptake of the HPV vaccine
that were identified by GPs included the availability of
the vaccine on site, the availability of information related
to the vaccine either on site or online, and positive opin-
ions from experts in the field. The availability of the
vaccine on site would certainly be more convenient
for patients, but they would still be required to attend
further consultations to complete the vaccine schedule.
Improving the availability of and access to information
about HPV vaccination is vital as many women believe
that they do not have sufficient information at their dis-
posal to allow them to make an informed decision about
whether or not to get vaccinated [9]. This information,
together with positive opinions from experts, may facili-
tate the uptake of the HPV vaccine because of the strong
link between high HPV-related knowledge and greater
intentions to vaccinate against HPV [33,34].
Our study is limited by the small number of GPs who
were interviewed. Although a financial incentive was of-
fered, the GPs in our study volunteered to participate
and, therefore, may represent a subgroup of GPs who
have a higher level of interest in HPV vaccination com-
pared with GPs who were randomly selected. This po-
tential bias may limit the generalisability of our findings;
however, we found that some of the barriers reported in
our study were also reported in similar studies from
other countries [26,35-37], which supports the relevance
of our study results to other countries even in the con-
text of differing health systems.
Another limitation is the fact that all of the GPs in our
study were from metropolitan Melbourne, Australia. Con-
sequently, their responses may not be representative of the
responses of GPs practicing elsewhere within Australia,
particularly in rural areas. Conducting a similar study on a
larger scale and also incorporating quantitative method-
ologies may provide a deeper understanding of the barriers
that were identified in our study.
Conclusions
Our study has identified some of the barriers and facilita-
tors to the delivery and uptake of the HPV vaccine in fe-
males aged 27 to 45 years, as perceived by GPs. Further
studies are necessary to determine which of these should
be targeted or prioritised for intervention. We must also
consider the views of women, particularly in relation to
the cost of the vaccine versus the available data on efficacy
for this age group and the risk of future exposure to HPV.
Their views, along with those of GPs, are likely to influ-
ence the design and effectiveness of intervention strategies
for improving the delivery and uptake of the HPV vaccine.
These strategies should also consider the potential role
of practice nurses in facilitating the delivery of the HPV
vaccine especially to high-risk patients who should be ac-
tively targeted. Improving and increasing the availability of
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ered in any intervention because of the importance of
educating women (especially those who are deemed
“high risk”) on its effectiveness in preventing certain
types of cancer.
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